Patients' treatment expectations may affect their treatment outcomes. Coauthor Johannes A. C. Laferton, PhD, joins JAMA Senior Editor Anne Cappola, MD, ScM, to discuss the latest article in JAMA's Communicating Medicine series, which explores how to help patients have a better experience and better outcomes with treatment. Related Content: Improving Patients’ Treatment Expectations
-------- Â
18:57
Lipoprotein(a): What Clinicians Should Know
Elevated levels of lipoprotein(a) are associated with higher rates of cardiovascular events. Author Samia Mora, MD, MHS, of Brigham and Women’s Hospital and Harvard Medical School discusses measurement and interpretation of lipoprotein (a) levels with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content: Lipoprotein(a)
-------- Â
19:01
Platelet Transfusion: Best Practice Guidelines
A central question in platelet transfusion is whether to follow a restrictive or liberal strategy in decisions about which patients should receive platelets. Author Ryan Metcalf, MD, University of Utah, discusses new clinical guidelines for platelet transfusion and more with JAMA Executive Editor Gregory Curfman, MD. Related Content: Platelet Transfusion Red Blood Cell Transfusion in the Intensive Care Unit Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care Red Blood Cell Transfusion Trends in Red Blood Cell, Plasma, and Platelet Transfusions in the United States, 1993-2014
-------- Â
13:53
Immune Thrombotic Thrombocytopenic Purpera (iTTP)
Immune thrombotic thrombocytopenic purpura (iTTP) is a rare coagulopathic disorder characterized by immune-mediated thrombocytopenia and microangiopathic hemolytic anemia, that can cause life-threatening thrombosis. Coauthor Allyson M. Pishko, MD, MSCE, of the University of Pennsylvania joins JAMA Associate Editor David Simel, MD, MHS, to discuss the recent review of iTTP published in JAMA. Related Content: Immune Thrombotic Thrombocytopenic Purpura
-------- Â
21:36
Microbiome and Risk for Cancer Outcomes
The human microbiome appears to influence risk for development and progression of cancer and response to treatment. Author Jennifer Wargo, MD, University of Texas M.D. Anderson Cancer Center, discusses basic science and clinical evidence regarding the human microbiome and cancer risk with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content: The Microbiome and Cancer
South Africa